JP2020079331A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020079331A5 JP2020079331A5 JP2020036818A JP2020036818A JP2020079331A5 JP 2020079331 A5 JP2020079331 A5 JP 2020079331A5 JP 2020036818 A JP2020036818 A JP 2020036818A JP 2020036818 A JP2020036818 A JP 2020036818A JP 2020079331 A5 JP2020079331 A5 JP 2020079331A5
- Authority
- JP
- Japan
- Prior art keywords
- invention described
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025018896A JP2025065367A (ja) | 2018-08-01 | 2025-02-07 | Ｃ５関連疾患の治療または予防用の医薬組成物およびｃ５関連疾患を治療または予防するための方法 |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862713211P | 2018-08-01 | 2018-08-01 | |
| US62/713,211 | 2018-08-01 | ||
| US201862764952P | 2018-08-17 | 2018-08-17 | |
| US62/764,952 | 2018-08-17 | ||
| US201862760204P | 2018-11-13 | 2018-11-13 | |
| US62/760,204 | 2018-11-13 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020025071A Division JP6672533B1 (ja) | 2018-08-01 | 2020-02-18 | Ｃ５関連疾患の治療または予防用の医薬組成物およびｃ５関連疾患を治療または予防するための方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025018896A Division JP2025065367A (ja) | 2018-08-01 | 2025-02-07 | Ｃ５関連疾患の治療または予防用の医薬組成物およびｃ５関連疾患を治療または予防するための方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020079331A JP2020079331A (ja) | 2020-05-28 |
| JP2020079331A5 true JP2020079331A5 (https=) | 2022-08-09 |
Family
ID=67660420
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019142108A Active JP6672516B2 (ja) | 2018-08-01 | 2019-08-01 | Ｃ５関連疾患の治療または予防用の医薬組成物およびｃ５関連疾患を治療または予防するための方法 |
| JP2020025071A Active JP6672533B1 (ja) | 2018-08-01 | 2020-02-18 | Ｃ５関連疾患の治療または予防用の医薬組成物およびｃ５関連疾患を治療または予防するための方法 |
| JP2020036818A Pending JP2020079331A (ja) | 2018-08-01 | 2020-03-04 | Ｃ５関連疾患の治療または予防用の医薬組成物およびｃ５関連疾患を治療または予防するための方法 |
| JP2025018896A Pending JP2025065367A (ja) | 2018-08-01 | 2025-02-07 | Ｃ５関連疾患の治療または予防用の医薬組成物およびｃ５関連疾患を治療または予防するための方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019142108A Active JP6672516B2 (ja) | 2018-08-01 | 2019-08-01 | Ｃ５関連疾患の治療または予防用の医薬組成物およびｃ５関連疾患を治療または予防するための方法 |
| JP2020025071A Active JP6672533B1 (ja) | 2018-08-01 | 2020-02-18 | Ｃ５関連疾患の治療または予防用の医薬組成物およびｃ５関連疾患を治療または予防するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025018896A Pending JP2025065367A (ja) | 2018-08-01 | 2025-02-07 | Ｃ５関連疾患の治療または予防用の医薬組成物およびｃ５関連疾患を治療または予防するための方法 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20210301004A1 (https=) |
| EP (2) | EP3829628B1 (https=) |
| JP (4) | JP6672516B2 (https=) |
| KR (5) | KR20200033348A (https=) |
| CN (1) | CN112512563A (https=) |
| AU (2) | AU2019315213B2 (https=) |
| BR (1) | BR112021001655A2 (https=) |
| CA (1) | CA3107618A1 (https=) |
| CR (1) | CR20210103A (https=) |
| DE (1) | DE112019003835T5 (https=) |
| ES (1) | ES2980137T3 (https=) |
| HR (1) | HRP20240823T1 (https=) |
| HU (1) | HUE067057T2 (https=) |
| IL (2) | IL324626A (https=) |
| MX (2) | MX2021000516A (https=) |
| MY (1) | MY210523A (https=) |
| PH (1) | PH12021550226A1 (https=) |
| PL (1) | PL3829628T3 (https=) |
| RS (1) | RS65630B1 (https=) |
| SG (1) | SG10202002898RA (https=) |
| SM (1) | SMT202400271T1 (https=) |
| TW (2) | TWI704157B (https=) |
| WO (1) | WO2020027279A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2892925T3 (es) | 2006-03-31 | 2022-02-07 | Chugai Pharmaceutical Co Ltd | Métodos para controlar la farmacocinética en sangre de anticuerpos |
| CN101874042B9 (zh) | 2007-09-26 | 2019-01-01 | 中外制药株式会社 | 利用cdr的氨基酸取代来改变抗体等电点的方法 |
| KR102057826B1 (ko) | 2008-04-11 | 2019-12-20 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복 결합하는 항원 결합 분자 |
| TWI812066B (zh) | 2010-11-30 | 2023-08-11 | 日商中外製藥股份有限公司 | 具有鈣依存性的抗原結合能力之抗體 |
| CN107207607B (zh) | 2014-12-19 | 2021-05-04 | 中外制药株式会社 | 抗-c5抗体及使用方法 |
| KR101860280B1 (ko) | 2014-12-19 | 2018-05-21 | 추가이 세이야쿠 가부시키가이샤 | 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법 |
| CN114773470A (zh) | 2015-02-05 | 2022-07-22 | 中外制药株式会社 | 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用 |
| US11359009B2 (en) | 2015-12-25 | 2022-06-14 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
| TWI693940B (zh) | 2016-08-05 | 2020-05-21 | 日商中外製藥股份有限公司 | Ｉｌ-８相關疾病之治療用或預防用組成物 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| ES2292236T3 (es) | 1998-04-02 | 2008-03-01 | Genentech, Inc. | Variantes de anticuerpos y sus fragmentos. |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| HU230769B1 (hu) | 1999-01-15 | 2018-03-28 | Genentech Inc. | Módosított effektor-funkciójú polipeptid-változatok |
| AU2001296594A1 (en) | 2000-10-10 | 2002-04-22 | Tanox, Inc. | Inhibition of complement c5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection |
| BRPI0211953B8 (pt) | 2001-08-17 | 2021-05-25 | Genentech Inc | anticorpo monoclonal ou fragmento de ligação a antígeno que se liga a c5 e c5a sem a prevenção da formação de c5b, linhagem celular, composição farmacêutica, bem como método in vitro para inibir a atividade de c5a e método de diagnóstico in vitro |
| ITMI20021527A1 (it) | 2002-07-11 | 2004-01-12 | Consiglio Nazionale Ricerche | Anticorpi anti componente c5 del complemento e loro uso |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| EP3263596A1 (en) | 2002-12-16 | 2018-01-03 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| US20070116710A1 (en) | 2004-02-03 | 2007-05-24 | Leonard Bell | Methods of treating hemolytic anemia |
| US20050169921A1 (en) | 2004-02-03 | 2005-08-04 | Leonard Bell | Method of treating hemolytic disease |
| KR100891620B1 (ko) | 2004-04-13 | 2009-04-02 | 에프. 호프만-라 로슈 아게 | 항-ｐ-셀렉틴 항체 |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| PL3167888T3 (pl) | 2006-03-15 | 2024-08-26 | Alexion Pharmaceuticals, Inc. | Leczenie pacjentów z napadową nocną hemoglobinurią za pomocą inhibitora dopełniacza |
| KR102057826B1 (ko) | 2008-04-11 | 2019-12-20 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복 결합하는 항원 결합 분자 |
| PY09026846A (es) | 2008-08-05 | 2015-09-01 | Novartis Ag | Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5 |
| LT2894165T (lt) | 2008-11-10 | 2023-03-10 | Alexion Pharmaceuticals, Inc. | Būdai ir kompozicijos, skirti su komplementu susijusių sutrikimų gydymui |
| SG183867A1 (en) | 2010-03-11 | 2012-10-30 | Rinat Neuroscience Corp | ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING |
| TWI667346B (zh) | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的FcRn親和力之抗體 |
| EP2975055A4 (en) * | 2013-01-31 | 2016-11-02 | Univ Seoul Nat R & Db Found | C5 ANTIBODIES AND METHOD FOR PREVENTING AND TREATING COMPLEMENT-MEDIATED ILLNESSES |
| CN107207607B (zh) | 2014-12-19 | 2021-05-04 | 中外制药株式会社 | 抗-c5抗体及使用方法 |
| JP6130983B2 (ja) * | 2015-02-27 | 2017-05-17 | 中外製薬株式会社 | Ｉｌ−６関連疾患治療用組成物 |
| EP3402816A1 (en) * | 2016-01-11 | 2018-11-21 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment |
| EP3408291A1 (en) | 2016-01-25 | 2018-12-05 | Shire Human Genetic Therapies, Inc. | Anti-c5 antibodies with enhanced ph switch |
| CA3080187A1 (en) * | 2017-10-26 | 2019-05-02 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus) |
| BR112020010916A2 (pt) * | 2017-12-04 | 2020-11-17 | Ra Pharmaceuticals, Inc | moduladores da atividade do complemento |
-
2019
- 2019-08-01 KR KR1020207007296A patent/KR20200033348A/ko not_active Ceased
- 2019-08-01 KR KR1020247023205A patent/KR20240115904A/ko active Pending
- 2019-08-01 AU AU2019315213A patent/AU2019315213B2/en active Active
- 2019-08-01 KR KR1020197036896A patent/KR20200033225A/ko not_active Ceased
- 2019-08-01 TW TW109108378A patent/TWI704157B/zh active
- 2019-08-01 BR BR112021001655-4A patent/BR112021001655A2/pt unknown
- 2019-08-01 IL IL324626A patent/IL324626A/en unknown
- 2019-08-01 PL PL19755447.0T patent/PL3829628T3/pl unknown
- 2019-08-01 SM SM20240271T patent/SMT202400271T1/it unknown
- 2019-08-01 TW TW108127358A patent/TWI701041B/zh active
- 2019-08-01 EP EP19755447.0A patent/EP3829628B1/en active Active
- 2019-08-01 HR HRP20240823TT patent/HRP20240823T1/hr unknown
- 2019-08-01 EP EP24174873.0A patent/EP4445913A3/en active Pending
- 2019-08-01 CN CN201980051238.8A patent/CN112512563A/zh active Pending
- 2019-08-01 MX MX2021000516A patent/MX2021000516A/es unknown
- 2019-08-01 KR KR1020217009235A patent/KR20210037743A/ko not_active Ceased
- 2019-08-01 KR KR1020217009233A patent/KR20210038697A/ko not_active Ceased
- 2019-08-01 ES ES19755447T patent/ES2980137T3/es active Active
- 2019-08-01 HU HUE19755447A patent/HUE067057T2/hu unknown
- 2019-08-01 CR CR20210103A patent/CR20210103A/es unknown
- 2019-08-01 DE DE112019003835.4T patent/DE112019003835T5/de active Pending
- 2019-08-01 IL IL280475A patent/IL280475B2/en unknown
- 2019-08-01 US US17/263,691 patent/US20210301004A1/en active Pending
- 2019-08-01 RS RS20240695A patent/RS65630B1/sr unknown
- 2019-08-01 SG SG10202002898RA patent/SG10202002898RA/en unknown
- 2019-08-01 MY MYPI2021000486A patent/MY210523A/en unknown
- 2019-08-01 JP JP2019142108A patent/JP6672516B2/ja active Active
- 2019-08-01 CA CA3107618A patent/CA3107618A1/en active Pending
- 2019-08-01 WO PCT/JP2019/030283 patent/WO2020027279A1/en not_active Ceased
-
2020
- 2020-02-18 JP JP2020025071A patent/JP6672533B1/ja active Active
- 2020-03-04 JP JP2020036818A patent/JP2020079331A/ja active Pending
-
2021
- 2021-01-14 MX MX2025010400A patent/MX2025010400A/es unknown
- 2021-01-29 PH PH12021550226A patent/PH12021550226A1/en unknown
-
2024
- 2024-08-02 AU AU2024205486A patent/AU2024205486A1/en not_active Abandoned
-
2025
- 2025-02-07 JP JP2025018896A patent/JP2025065367A/ja active Pending